In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017.
Lysins are direct lytic agents which act through enzymatic cell-wall-hydrolysis and represent a potential new class of antimicrobial agents in development to treat antibiotic-resistant bacterial infections. Exebacase (CF-301) is a first-in-class lysin now in clinical development for the treatment of Staphylococcus aureus (S. aureus) bacteremia and infective endocarditis (IE) when used in addition to conventional antibiotics. Exebacase and comparator antibiotics were tested by broth microdilution against a set of 535 clinical MSSA and MRSA isolates collected from 2015 to 2017 throughout the United States, Europe and South America. All S. aureus isolates were inhibited by ≤1 mg/L exebacase (MIC50/90, 0.5/1 mg/L) with a range of 0.25-1 mg/L. No difference in susceptibility was observed between the MSSA and MRSA isolates. Exebacase was uniformly and equivalently active against all recent clinical MSSA and MRSA surveillance isolates from a broad survey across 3 continents.